

EGFR/ErbB1

Catalog # PVGS1527

Product Information

| | |
|----------------------------------|--|
| Primary Accession Species | P00533-1 Human |
| Sequence | Leu25-Ser645 |
| Purity | > 95% as analyzed by SDS-PAGE |
| Endotoxin Level | |
| Biological Activity | Measured by its ability to bind rhEGF in a functional ELISA with an estimated KD |
| Expression System | CHO |
| Formulation | Lyophilized from a 0.2 μ m filtered solution in PBS. |
| Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O or PBS up to 100 μ g/ml. |
| Storage & Stability | Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |

Additional Information

| | |
|--------------------------|--|
| Target Background | EGF Receptor, also known as ERBB, ERBB1 and HER1, is a type I transmembrane protein belonging to the tyrosine protein kinase family. It belongs to a family of tyrosine kinase receptors including Human EGF Receptors (HER) 2, 3, and 4 which all play important roles in cell growth and differentiation. Their primary ligands are EGF, Heparin-Binding EGF and Transforming Growth Factor α . Upon ligand binding, EGFR undergoes asymmetric dimerization, composed of an "activator" and a "receiver". EGFR and its family members are dysregulated in numerous cancers. In particular, EGFR is overexpressed in many epithelial solid tumors. Evidence suggests EGFR is an excellent target for pharmacologic intervention in Non Small Cell Lung Cancer (NSCLC) due to its high level of expression and prominent role in tumor growth and metastasis. |
|--------------------------|--|

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.